AI in Drug Development: How OpenAI's Acquisition of Orchestra Bio is Revolutionizing the Market
AI 요약 정보
- OpenAI announces Orchestra Bio acquisition, plans Rosalind link
- Galux, Syntekabio and OncoCross develop AI drug tools
- Experts say AI drug candidates need validation and funding
